Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Pembrolizumab in R/M HNSCC
NCT05252429Phase 2Active, not recruiting
- Sponsor
- Hokkaido University Hospital
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Hokkaido University Hospital. Primary endpoint: Overall Response Rate at 1 year. Started Jul 2022; status: active, not recruiting.
02
Drugs
docetaxelpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05252429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252429.